PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Download All
Learn how experts around the world use PARP inhibitors to optimally manage patients with pancreatic cancer and BRCA1/2 or other alterations causing homologous repair deficiency with focused commentaries, a podcast series, an expert video roundtable, and downloadable slideset.
Dirk Arnold, MD, PhD
Elena Gabriela Chiorean, MD
person default
Michel Ducreux, MD, PhD
Eileen M. O'Reilly, MD
Philip Agop Philip, MD, PhD, FRCP
person default
Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

ClinicalThought Commentaries

With the approval of olaparib, how will your treatment of patients with pancreatic cancer change?

Dirk Arnold, MD, PhD Released: October 5, 2021

How might the use of PARP inhibitors evolve in the treatment of pancreatic cancer? Read this commentary from Dr Philip Philip.

Philip Agop Philip, MD, PhD, FRCP Released: January 31, 2022

Audio Podcast Series with Podcast Pearls Transcript

Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: October 26, 2021

In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: November 3, 2021

Listen to Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitors that are being investigated for the treatment of pancreatic cancer.

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: February 21, 2022

In this downloadable PDF summary from a CCO podcast, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, compare the role and use of PARP inhibitors in the treatment of pancreatic cancer between the United States and Europe.

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Expert Video Roundtable

In this video roundtable, watch 3 experts give their perspectives on the optimal management of patients with pancreatic cancer using PARP inhibitors, as well as emerging strategies with PARP inhibitors that they find promising.

Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.

Dirk Arnold, MD, PhD person default Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Released: December 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings